Analyzing Nanoparticles in Cancer Cells

The most commonly used analysis of biological samples containing nanomaterials, that significantly scatter light, is dark field illumination. It is also an exceptional tool to identify the location and composition of nanomaterials embedded in cells when combined with hyperspectral imaging. A highly efficient dark field condenser can be added to Photon etc.’s hyperspectral imager, IMA™, to generate high contrast images of biological samples.

Dark field image of human breast cancer cells tagged with gold nano particles (60 nm size).

Figure 1. Dark field image of human breast cancer cells tagged with gold nano particles (60 nm size).

Photon etc.’s hyperspectral filter’s high throughput gives quick access to high resolution spectrally resolved images. The whole area in the field of view is captured by the camera, so it is possible to gather spatial and spectral details in real time, with the ability to record spectrally resolved videos to follow the dynamics of cells and luminescent nanoscale components.

PHySpec™ Software

In order to identify the smallest variations of single and aggregated nanoparticles, PHySpec™, Photon etc's software facilitates principal component analysis (PCA).

A sample of MDA-MB-23 human breast cancer cells has been tagged with 60 nm gold nanoparticles (GNPs) and exposed to a dark field illumination on the entire field of view, with the purpose of demonstrating the capabilities of IMA™ to analyze nanomaterials in biological systems, (Figure 1).

An area of 150x112 μm2 was imaged, with a 60X objective, an exposition time of 2 s per wavelength and a step of 2 nm. It only took a few minutes for a complete analysis of over a million spectra, all them covering the whole visible spectrum.

Figure 2 shows the 550 nm image taken from the dark field hyperspectral cube of the breast cancer. GNPs show a sharp peak at approximately 550 nm, whereas cells typically have a flat scattering spectrum. After PCA software processing, the GNPs are marked with a green coloring.

Manochromatic image at 550 nm. GNPs marked in green after PCA.

Figure 2. Manochromatic image at 550 nm. GNPs marked in green after PCA.

Inspecting Nanoparticles in Cancer Cells

The magnification of a breast cancer cell (Figure 3a) and the spectra of the regions containing GNPs (some examples in Figure 3b) confirmed the presence of single 60 nm NPs (peak at 550 nm) and their aggregates (peaks red-shifted). No GNPs were detected by the hyperspectral camera in the areas between the cells.

Magnnification of breast cancer cell (a) and spectra of GNPs in different areas (b).

Figure 3. Magnnification of breast cancer cell (a) and spectra of GNPs in different areas (b).

Results kindly provided by: David Rioux, Éric Bergeron and Michel Meunier, at École Polytechnique of Montreal, Quebec, Canada.

Image

This information has been sourced, reviewed and adapted from materials provided by Photon etc.

For more information on this source, please visit Photon etc.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Photon etc. (2024, February 20). Analyzing Nanoparticles in Cancer Cells. AZoNano. Retrieved on May 02, 2024 from https://www.azonano.com/article.aspx?ArticleID=4935.

  • MLA

    Photon etc. "Analyzing Nanoparticles in Cancer Cells". AZoNano. 02 May 2024. <https://www.azonano.com/article.aspx?ArticleID=4935>.

  • Chicago

    Photon etc. "Analyzing Nanoparticles in Cancer Cells". AZoNano. https://www.azonano.com/article.aspx?ArticleID=4935. (accessed May 02, 2024).

  • Harvard

    Photon etc. 2024. Analyzing Nanoparticles in Cancer Cells. AZoNano, viewed 02 May 2024, https://www.azonano.com/article.aspx?ArticleID=4935.

Ask A Question

Do you have a question you'd like to ask regarding this article?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.